The central paradox the authors dissect is the abscopal effect, a phenomenon first described in the context of radiation therapy and named from the Greek “ab” and “skopos,” suggesting a target away from the intended one. In rare and notoriously unpredictable cases, destroying a tumor at one site triggers shrinkage of untreated metastases elsewhere in the body, implying that the local treatment somehow activated a systemic immune response capable of hunting cancer cells it had never physically touched. For most of the history of oncology, abscopal responses were little more than a curiosity, reported sporadically and explained hand-wavingly as immune effects. What has changed is the arrival of immune checkpoint inhibitors, drugs such as anti-PD-1 and anti-PD-L1 antibodies that release the molecular brakes keeping T cells exhausted. The review frames the abscopal effect as a model system for understanding systemic immune activation precisely because checkpoint blockade can convert the transient, dampened immunity generated by ablation into something sustained and clonally expansive.

The mechanistic logic of the synergy unfolds in stages that the review maps with unusual clarity. Ablation first acts as an antigen release event: dying tumor cells expose and release proteins that were previously sequestered, along with calreticulin, ATP, and other damage signals that dendritic cells recognize as evidence of an aberrant, dangerous death rather than quiet apoptosis. These dendritic cells engulf the debris, migrate to draining lymph nodes, and present tumor-derived peptides on major histocompatibility molecules to naïve T cells, a process known as immune priming. Some modalities are particularly adept at this. Cryoablation, which freezes cells rather than coagulating them, tends to preserve antigen structure and has been shown in mouse models to trigger type I interferon-dependent antitumor immunity, in part through the cGAS-STING cytosolic DNA sensing pathway. Mechanical high-intensity focused ultrasound and histotripsy generate unique tumor debris that enhances dendritic cell-mediated T cell activation, and irreversible electroporation has been shown to augment checkpoint immunotherapy while promoting tumor antigen-specific tissue-resident memory CD8+ T cells.

Yet priming alone is not enough, and this is where the review is most candid about the immunobiology that separates laboratory promise from clinical reality. The tumor microenvironment into which newly activated T cells must travel is often immunologically hostile, densely infiltrated by regulatory T cells, tumor-associated macrophages skewed toward suppressive phenotypes, and myeloid cells secreting inhibitory cytokines. Even if cytotoxic T lymphocytes are successfully primed against ablation-released antigens, they frequently arrive at distant tumor sites exhausted, their receptors engaged by PD-L1 and related ligands, their metabolism deranged. Immune checkpoint inhibitors address precisely this bottleneck: they do not create tumor-specific T cells but instead preserve and prolong the function of those that ablation has helped to generate. The combination therefore follows a rational division of labor, with ablation supplying antigen and inflammatory context, functioning as an in situ vaccine, while immunotherapy supplies the survival signals that allow the resulting T cell response to expand, persist, traffic, and kill across anatomical compartments. Preclinical studies across multiple solid tumors, including lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and melanoma, have shown that this pairing can promote immune priming, increase infiltration of cytotoxic lymphocytes, and produce systemic disease control where either approach alone fails.

Clinical evidence is accumulating, though unevenly, and the review carefully catalogues where the concept has moved from mouse to human. In lung cancer, microwave ablation has been reported to enhance local T cell abundance and strengthen systemic immune responses, and cryoablation combined with PD-1 blockade has produced striking responses in metastatic disease. A window-of-opportunity trial in early-stage breast cancer combined preoperative camrelizumab with microwave ablation, providing a direct look at immune changes in the treated tumor before surgery. In hepatocellular carcinoma, where ablation is already a standard locoregional therapy, combinations with checkpoint inhibitors are being explored intensively, although the review notes that the hepatocellular carcinoma microenvironment is more immunosuppressive than that of colorectal liver metastases, complicating extrapolation between tumor types. Notably, individual case reports describe abscopal responses and even reversal of checkpoint inhibitor resistance following radiofrequency ablation in patients with refractory disease, and retrospective analyses in metastatic lung cancer have documented abscopal phenomena when radiotherapy was added to immunotherapy. These are signals, the authors emphasize, not proof, and the rarity of such responses remains the field’s defining challenge.

Perhaps the most technically interesting section of the review concerns the choice of ablative modality, which turns out to be anything but interchangeable. Radiofrequency ablation and microwave ablation are both thermal techniques that coagulate tissue, but microwave energy heats faster and reaches higher temperatures, producing different cell death kinetics and, evidence suggests, different immune signatures. Cryoablation, by contrast, kills through ice crystal formation and osmotic rupture, leaving antigens and tumor architecture relatively intact and preserving epitopes that might otherwise be denatured. High-intensity focused ultrasound can operate in thermal or purely mechanical modes, and histotripsy, which fractionates tissue with pulsed ultrasound cavitation, generates debris with distinctive immune-stimulating properties. Photothermal and photodynamic therapies, increasingly delivered through engineered nanoparticles, add another layer of programmability, with nanoplatforms now capable of repolarizing tumor-associated macrophages, delivering STING agonists, and creating autologous cancer vaccines from the patient’s own ablated tissue. The immunogenic character of cell death induced at different temperatures, one cited study found, varies measurably in hepatocellular carcinoma cells, meaning that a radiation oncologist’s choice of energy, dose, and timing is, in effect, an immunological design decision.

That decision is complicated by a darker caveat the review does not shy away from: incomplete ablation may backfire. Studies of insufficient thermal ablation have documented increased tumorigenesis at ablation margins, and analyses of hepatocellular carcinoma treated with transarterial chemoembolization plus radiofrequency ablation found that inadequate ablation associated with intrahepatic and extrahepatic metastasis. Hypoxic, inflamed, partially viable tissue at the ablation edge can recruit suppressive myeloid cells and promote angiogenesis, converting a well-intentioned immune-priming event into a pro-tumor insult. This finding sharpens the translational imperative: if ablation is to serve as an in situ vaccine, the ablation must be adequate, the inflammatory context must be productive, and the checkpoint blockade must be present at the right time to rescue the primed T cell response before it collapses into exhaustion or deletion.

Timing, in fact, emerges as one of the most stubborn unresolved variables. Should checkpoint inhibitors be given before ablation, so that T cells are already released from inhibition when antigen floods the system, or after, so that the drugs encounter a maximally primed immune repertoire? Should ablation be complete or deliberately partial, leaving residual antigen-rich tissue as a vaccine substrate? Which lesion should be ablated in a patient with multiple metastases, and does lesion size matter, as one study of liver metastatic melanoma receiving cryoablation plus PD-1 blockade suggests it does? None of these questions has a definitive answer, and the review identifies the absence of biomarker-driven patient stratification as a central obstacle. Candidate biomarkers are proliferating, from PD-L1 expression and interferon-gamma gene signatures to circulating tumor DNA kinetics, T cell receptor clonality, liquid biopsy measurements of minimal residual disease, and radiomics features extracted from imaging. What is lacking is large-scale validation linking any of these to abscopal responses or to outcomes of specific ablation-immunotherapy combinations in defined tumor types.

The translational roadmap the authors sketch is correspondingly ambitious. It calls for mechanistically informed clinical trial designs that treat modality, dose, timing, and immunotherapy schedule as coordinated experimental variables rather than independent choices; for comparative immunology that maps how each energy-based technique shapes antigen release, dendritic cell activation, and T cell trafficking; for integration of nanotechnology, cytokine engineering, and STING agonists to amplify the in situ vaccine effect; and for artificial intelligence-driven multi-omics modeling to predict which patients and which tumors are most likely to respond. The stakes are considerable. Checkpoint inhibitors have transformed outcomes in a subset of cancers but leave the majority of patients with solid tumors without durable benefit, often because their tumors are immunologically cold, devoid of T cells and antigen presentation. Ablation offers a physical means of heating those tumors up, converting individual lesions into antigen depots and inflammatory scaffolds. If the field can convert what is today a rare and unpredictable abscopal event into a reproducible therapeutic strategy, the review concludes, local tumor destruction will have fulfilled a promise far larger than the sum of the tissue it removes: the promise of teaching the immune system, in a single controlled injury, to recognize and eliminate cancer throughout the entire body.

Subject of Research: Mechanisms of abscopal effect and synergy between tumor ablation and immunotherapy in cancer

Article Title: Ablation–immunotherapy synergy in cancer: mechanisms of the abscopal effect, emerging clinical applications, and translational roadmaps for next-generation onco-immunology

Article References: Hama, M. A., Madhat, M. A., Awlqadr, F. H., Mahmood, A. H. A., Abdalla, R. A., Ali, R. K., Kareem, S. H. T., Hama, N. E., Hamalaw, S. R., & AL-Farga, A. M. (2026). Ablation–immunotherapy synergy in cancer: mechanisms of the abscopal effect, emerging clinical applications, and translational roadmaps for next-generation onco-immunology. Medical Oncology, 43(11), Article 313. https://doi.org/10.1007/s12032-026-03396-2

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03396-2

Keywords: abscopal effect, tumor ablation, immunotherapy, immune checkpoint inhibitors, cryoablation, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound, immunogenic cell death, tumor microenvironment, cGAS-STING, in situ vaccination